STOCK TITAN

[Form 4] Associated Banc-Corp Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Franklin Resources, Inc., together with principal shareholders Charles B. Johnson and Rupert H. Johnson, Jr., filed Amendment No. 1 to Schedule 13G covering Adverum Biotechnologies (ADVM) as of 30 Jun 2025.

  • Beneficial ownership: 0 shares; 0.0 % of the common stock.
  • Sole or shared voting power: none.
  • The group therefore certifies ownership of “<5 %” and is no longer a reporting 5 % holder.
  • Signatures executed 01 Aug 2025 by Assistant Secretary Thomas C. Mandia under powers of attorney.

The filing, made under Schedule 13G Rule 13d-1, indicates a complete exit by a previously significant institutional investor. No financial results, transaction details or strategic commentary are provided.

Franklin Resources, Inc., insieme agli azionisti principali Charles B. Johnson e Rupert H. Johnson, Jr., ha presentato l'Emendamento N. 1 al Modulo 13G relativo a Adverum Biotechnologies (ADVM) al 30 giugno 2025.

  • Possesso effettivo: 0 azioni; 0,0% del capitale sociale.
  • Potere di voto esclusivo o condiviso: nessuno.
  • Il gruppo certifica quindi una proprietà inferiore al “5%” e non è più un azionista segnalante al 5%.
  • Le firme sono state apposte il 01 agosto 2025 dall’Assistente Segretario Thomas C. Mandia in virtù di procure.

La comunicazione, presentata ai sensi della Regola 13d-1 del Modulo 13G, indica un’uscita completa da parte di un investitore istituzionale precedentemente rilevante. Non sono forniti risultati finanziari, dettagli sulle transazioni o commenti strategici.

Franklin Resources, Inc., junto con los principales accionistas Charles B. Johnson y Rupert H. Johnson, Jr., presentó la Enmienda N.º 1 al Anexo 13G referente a Adverum Biotechnologies (ADVM) con fecha 30 de junio de 2025.

  • Propiedad beneficiaria: 0 acciones; 0,0 % del capital social.
  • Poder de voto exclusivo o compartido: ninguno.
  • Por lo tanto, el grupo certifica una propiedad inferior al “5 %” y ya no es un titular reportante del 5 %.
  • Las firmas fueron ejecutadas el 01 de agosto de 2025 por el Secretario Asistente Thomas C. Mandia bajo poderes notariales.

La presentación, realizada bajo la Regla 13d-1 del Anexo 13G, indica una salida completa de un inversor institucional previamente significativo. No se proporcionan resultados financieros, detalles de la transacción ni comentarios estratégicos.

Franklin Resources, Inc.는 주요 주주 Charles B. JohnsonRupert H. Johnson, Jr.와 함께 Adverum Biotechnologies (ADVM)에 관한 2025년 6월 30일자 13G 스케줄 수정서 1호를 제출했습니다.

  • 실질 소유주: 0주; 보통주 0.0%.
  • 단독 또는 공동 의결권: 없음.
  • 따라서 이 그룹은 “5% 미만” 소유를 인증하며 더 이상 5% 이상 보고 의무가 있는 주주가 아닙니다.
  • 서명은 2025년 8월 1일 Thomas C. Mandia 부비서관이 위임장에 따라 수행했습니다.

이 제출 서류는 13G 스케줄 13d-1 규칙에 따라 작성되었으며, 이전에 중요한 기관 투자자가 완전히 철수했음을 나타냅니다. 재무 결과, 거래 세부사항 또는 전략적 논평은 제공되지 않았습니다.

Franklin Resources, Inc., conjointement avec les principaux actionnaires Charles B. Johnson et Rupert H. Johnson, Jr., a déposé l'Amendement n°1 au Schedule 13G concernant Adverum Biotechnologies (ADVM) au 30 juin 2025.

  • Détention effective : 0 actions ; 0,0 % du capital social.
  • Pouvoir de vote exclusif ou partagé : aucun.
  • Le groupe certifie donc une détention inférieure à “5 %” et n’est plus un détenteur déclarant à 5 %.
  • Les signatures ont été apposées le 1er août 2025 par le secrétaire adjoint Thomas C. Mandia en vertu de procurations.

Le dépôt, effectué selon la règle 13d-1 du Schedule 13G, indique une sortie complète d’un investisseur institutionnel auparavant significatif. Aucun résultat financier, détail de transaction ou commentaire stratégique n’est fourni.

Franklin Resources, Inc. hat zusammen mit den Hauptaktionären Charles B. Johnson und Rupert H. Johnson, Jr. die Änderung Nr. 1 zum Schedule 13G für Adverum Biotechnologies (ADVM) zum Stichtag 30. Juni 2025 eingereicht.

  • Wirtschaftliches Eigentum: 0 Aktien; 0,0 % des Stammkapitals.
  • Alleinige oder gemeinsame Stimmrechte: keine.
  • Die Gruppe bestätigt somit einen Besitz von unter „5 %“ und ist kein meldepflichtiger 5-%-Anteilseigner mehr.
  • Die Unterschriften wurden am 01. August 2025 vom Assistant Secretary Thomas C. Mandia aufgrund von Vollmachten geleistet.

Die Einreichung nach Schedule 13G Regel 13d-1 signalisiert einen vollständigen Ausstieg eines zuvor bedeutenden institutionellen Investors. Finanzielle Ergebnisse, Transaktionsdetails oder strategische Kommentare werden nicht bereitgestellt.

Positive
  • None.
Negative
  • Franklin Resources, Inc. and its principal shareholders report 0 shares and 0 % ownership, confirming a full exit from ADVM.

Insights

TL;DR: Franklin Resources declares 0 % ADVM stake; removal of large holder can pressure sentiment and liquidity.

The amendment confirms that Franklin Resources and the Johnson family now hold zero ADVM shares and possess no voting or dispositive power. Their departure eliminates a once-material institutional backer, potentially reducing stable ownership and increasing free float. While the document gives no rationale, the disappearance of a concentrated holder often signals diminished conviction and could introduce supply overhang from prior sales. From a portfolio-allocation view, the change is negative for investor confidence, though impact depends on market absorption of earlier disposals.

TL;DR: Filing is regulatory housekeeping; confirms the filers are below 5 % threshold.

This Schedule 13G/A fulfills disclosure obligations once ownership falls under 5 %. It clarifies that neither Franklin Resources nor its principals influence ADVM governance, as they hold no voting rights. Procedurally, the statement cleans the record and removes them from future 13D/G amendments unless a new position is built. Governance impact is neutral beyond the transparency benefit.

Franklin Resources, Inc., insieme agli azionisti principali Charles B. Johnson e Rupert H. Johnson, Jr., ha presentato l'Emendamento N. 1 al Modulo 13G relativo a Adverum Biotechnologies (ADVM) al 30 giugno 2025.

  • Possesso effettivo: 0 azioni; 0,0% del capitale sociale.
  • Potere di voto esclusivo o condiviso: nessuno.
  • Il gruppo certifica quindi una proprietà inferiore al “5%” e non è più un azionista segnalante al 5%.
  • Le firme sono state apposte il 01 agosto 2025 dall’Assistente Segretario Thomas C. Mandia in virtù di procure.

La comunicazione, presentata ai sensi della Regola 13d-1 del Modulo 13G, indica un’uscita completa da parte di un investitore istituzionale precedentemente rilevante. Non sono forniti risultati finanziari, dettagli sulle transazioni o commenti strategici.

Franklin Resources, Inc., junto con los principales accionistas Charles B. Johnson y Rupert H. Johnson, Jr., presentó la Enmienda N.º 1 al Anexo 13G referente a Adverum Biotechnologies (ADVM) con fecha 30 de junio de 2025.

  • Propiedad beneficiaria: 0 acciones; 0,0 % del capital social.
  • Poder de voto exclusivo o compartido: ninguno.
  • Por lo tanto, el grupo certifica una propiedad inferior al “5 %” y ya no es un titular reportante del 5 %.
  • Las firmas fueron ejecutadas el 01 de agosto de 2025 por el Secretario Asistente Thomas C. Mandia bajo poderes notariales.

La presentación, realizada bajo la Regla 13d-1 del Anexo 13G, indica una salida completa de un inversor institucional previamente significativo. No se proporcionan resultados financieros, detalles de la transacción ni comentarios estratégicos.

Franklin Resources, Inc.는 주요 주주 Charles B. JohnsonRupert H. Johnson, Jr.와 함께 Adverum Biotechnologies (ADVM)에 관한 2025년 6월 30일자 13G 스케줄 수정서 1호를 제출했습니다.

  • 실질 소유주: 0주; 보통주 0.0%.
  • 단독 또는 공동 의결권: 없음.
  • 따라서 이 그룹은 “5% 미만” 소유를 인증하며 더 이상 5% 이상 보고 의무가 있는 주주가 아닙니다.
  • 서명은 2025년 8월 1일 Thomas C. Mandia 부비서관이 위임장에 따라 수행했습니다.

이 제출 서류는 13G 스케줄 13d-1 규칙에 따라 작성되었으며, 이전에 중요한 기관 투자자가 완전히 철수했음을 나타냅니다. 재무 결과, 거래 세부사항 또는 전략적 논평은 제공되지 않았습니다.

Franklin Resources, Inc., conjointement avec les principaux actionnaires Charles B. Johnson et Rupert H. Johnson, Jr., a déposé l'Amendement n°1 au Schedule 13G concernant Adverum Biotechnologies (ADVM) au 30 juin 2025.

  • Détention effective : 0 actions ; 0,0 % du capital social.
  • Pouvoir de vote exclusif ou partagé : aucun.
  • Le groupe certifie donc une détention inférieure à “5 %” et n’est plus un détenteur déclarant à 5 %.
  • Les signatures ont été apposées le 1er août 2025 par le secrétaire adjoint Thomas C. Mandia en vertu de procurations.

Le dépôt, effectué selon la règle 13d-1 du Schedule 13G, indique une sortie complète d’un investisseur institutionnel auparavant significatif. Aucun résultat financier, détail de transaction ou commentaire stratégique n’est fourni.

Franklin Resources, Inc. hat zusammen mit den Hauptaktionären Charles B. Johnson und Rupert H. Johnson, Jr. die Änderung Nr. 1 zum Schedule 13G für Adverum Biotechnologies (ADVM) zum Stichtag 30. Juni 2025 eingereicht.

  • Wirtschaftliches Eigentum: 0 Aktien; 0,0 % des Stammkapitals.
  • Alleinige oder gemeinsame Stimmrechte: keine.
  • Die Gruppe bestätigt somit einen Besitz von unter „5 %“ und ist kein meldepflichtiger 5-%-Anteilseigner mehr.
  • Die Unterschriften wurden am 01. August 2025 vom Assistant Secretary Thomas C. Mandia aufgrund von Vollmachten geleistet.

Die Einreichung nach Schedule 13G Regel 13d-1 signalisiert einen vollständigen Ausstieg eines zuvor bedeutenden institutionellen Investors. Finanzielle Ergebnisse, Transaktionsdetails oder strategische Kommentare werden nicht bereitgestellt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Meyer Derek S.

(Last) (First) (Middle)
C/O ASSOCIATED BANC-CORP
433 MAIN STREET

(Street)
GREEN BAY WI 54301

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ASSOCIATED BANC-CORP [ ASB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock $0.01 Par Value 08/04/2025 F(1) 5,883 D $24.09 51,161.379 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares were surrendered to satisfy tax withholding obligations arising from the vesting of restricted stock - 3rd tranche vesting of Sign-on Bonus.
/s/ Lynn M. Floeter, attorney-in-fact for Derek S. Meyer 08/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ADVM shares does Franklin Resources report owning?

The filing lists 0 shares, representing 0.0 % of the outstanding common stock.

What is the event date for this Schedule 13G/A on ADVM?

30 June 2025 is the date triggering the filing requirement.

Who are the reporting persons in this ADVM Schedule 13G/A?

Franklin Resources, Inc., Charles B. Johnson, and Rupert H. Johnson, Jr.

What voting or dispositive power do the filers retain?

They report no sole or shared voting or dispositive power over ADVM shares.

When was the filing signed and by whom?

Signed on 01 Aug 2025 by Thomas C. Mandia, Assistant Secretary, under power of attorney.

Why does this filing matter to ADVM investors?

It confirms that a previously significant institutional holder has completely exited, potentially affecting ownership structure and market sentiment.
Associated Banc Corp

NYSE:ASB

ASB Rankings

ASB Latest News

ASB Latest SEC Filings

ASB Stock Data

4.00B
164.25M
0.78%
87.85%
3.29%
Banks - Regional
State Commercial Banks
Link
United States
GREEN BAY